Maryland is positioning itself for a meaningful role in the next phase of U.S. bioindustrial manufacturing, with F3 Tech tapped to lead a proposed $40 million, multi-user biomanufacturing facility under the federal BioMADE program. The effort, developed in collaboration with the Maryland Department of Commerce, reflects both a long-term strategy to diversify the state’s biotechnology economy and a broader national push to strengthen domestic manufacturing capacity.
At its core, the proposal is about infrastructure — and who gets access to it. The envisioned facility would serve as shared biomanufacturing capacity for industry, academic, and economic development partners, lowering barriers for companies developing next-generation bioindustrial technologies. If successful, it would place Maryland more firmly within the federal government’s evolving manufacturing ecosystem, particularly as biomanufacturing becomes a strategic priority for economic resilience and national security.
The initiative aligns with BioMADE, a Manufacturing USA institute launched by the U.S. Department of Defense in 2020. BioMADE’s mandate is expansive: accelerate biomanufacturing innovation, strengthen supply chains, reshore critical production, and build a workforce capable of supporting a rapidly scaling sector. With more than 325 member organizations across 40 states, BioMADE has become one of the most influential federal levers shaping how and where bioindustrial capacity is built.
For Maryland, the proposal represents a convergence of timing and intent. The Department of Commerce has asked F3 Tech to identify an industry anchor and assemble a coalition of partners to define the facility’s site, operating model, and long-term sustainability. While details are still emerging, the multi-user approach mirrors national trends favoring shared infrastructure over single-tenant builds — particularly for early-stage and scaling companies that need access to pilot and demonstration-scale manufacturing without the capital burden of owning facilities outright.
“This opportunity represents the culmination of a decade of F3 Tech’s work to advance and diversify the biotechnology economy in Maryland,” said Mike Thielke, executive director of F3 Tech, in a statement. He also pointed to the proposal’s proximity to Washington, D.C., and the potential for collaboration with federal research assets, including the U.S. Department of Agriculture’s Agricultural Research Center in Beltsville, as a way to strengthen regulatory engagement with emerging technologies.
F3 Tech operates as a program of the Eastern Shore Entrepreneurship Center, a nonprofit based in Easton that has focused on commercialization and applied innovation across agriculture, aquaculture, and bioindustrial technology. That applied lens is particularly relevant as biomanufacturing expands beyond traditional biopharma into areas such as industrial enzymes, sustainable materials, and biobased chemicals — sectors where Maryland has scientific depth but has historically lacked dedicated manufacturing pathways.
The broader implications extend beyond any single facility. Federal investments like BioMADE are increasingly shaping where talent is trained, where companies choose to locate, and how regions compete for advanced manufacturing jobs. For Maryland — already home to dense federal research infrastructure and a strong life sciences workforce — the proposal signals an effort to translate those assets into scalable, production-oriented capabilities.
Businesses and organizations interested in participating in the proposal development process have been encouraged to contact F3 Tech by the end of March 2026. Whether the project ultimately moves forward will depend on federal selection and partner alignment, but the move itself underscores a growing recognition: in biomanufacturing, infrastructure is strategy. And Maryland is signaling that it intends to be part of the national buildout shaping the future of the bioeconomy.
